Hospital
UPMC ST Margaret
UPMC ST Margaret was paid $5.40M by Medicaid between Dec 2019 and Dec 2024, across 223 billing codes. Its largest line is 99284, emergency room visit (serious) — 33% of everything it billed.
33Billing provider infoUPMC ST MARGARET
PITTSBURGH, PA 15215
PITTSBURGH, PA 15215
33aNPI1790795359assigned 08/08/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.40M
24GClaims222,321
24DCodes billed223
24AFirst – last monthDec 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#55 of 154
Median peer was paid$2.82M
This provider vs. median1.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 65 | $144.76 | |
| 2020 | 22,722 | $498K | |
| 2021 | 107,596 | $2.93M | |
| 2022 | 38,808 | $807K | |
| 2023 | 34,048 | $694K | |
| 2024incomplete | 19,082 | $474K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 33% | 12,360 | 11,953 | $1.78M |
| G0378 | Hospital observation service, per hour | 17% | 3,717 | 1,468 | $912K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.6% | 3,280 | 3,126 | $520K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.6% | 2,793 | 2,708 | $250K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.3% | 1,386 | 1,349 | $176K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.4% | 7,306 | 6,959 | $131K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 2.1% | 4,257 | 3,865 | $112K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 1.7% | 390 | 381 | $93K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 1.3% | 464 | 453 | $69K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 1.1% | 345 | 335 | $59K |
| 95811 | 1.1% | 140 | 135 | $59K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 393 | 389 | $54K |
211 more codes
| 72141 | <1% | 244 | $52K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,723 | $50K |
| 73221 | <1% | 209 | $49K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 249 | $47K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,784 | $45K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,794 | $43K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,164 | $39K |
| 80053 | Comprehensive metabolic panel | <1% | 5,313 | $36K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 914 | $36K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 580 | $33K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 31 | $32K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 112 | $29K |
| 84484 | <1% | 4,370 | $27K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 481 | $26K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 550 | $26K |
| 71250 | <1% | 398 | $23K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 462 | $21K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 190 | $20K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 322 | $19K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,443 | $17K |
| 80050 | General health panel | <1% | 380 | $14K |
| 62323 | <1% | 166 | $14K | |
| 80076 | <1% | 2,602 | $14K | |
| 83605 | <1% | 2,795 | $14K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 781 | $13K |
| 83880 | <1% | 650 | $13K | |
| 83690 | <1% | 3,875 | $12K | |
| 85730 | <1% | 2,896 | $12K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,041 | $11K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 361 | $11K |
| 93971 | <1% | 222 | $11K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 382 | $11K |
| J3490 | Unclassified drugs | <1% | 3,409 | $11K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 254 | $10K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 43 | $10K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 721 | $9K |
| 70496 | <1% | 88 | $9K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,427 | $9K |
| 76536 | <1% | 184 | $8K | |
| 85610 | <1% | 3,844 | $8K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 417 | $8K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 291 | $7K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 136 | $7K |
| Q3014 | Telehealth originating site facility fee | <1% | 541 | $7K |
| 80061 | Lipid panel | <1% | 665 | $7K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 175 | $7K |
| 83735 | <1% | 1,868 | $7K | |
| 70498 | <1% | 69 | $6K | |
| 64721 | <1% | 13 | $6K | |
| 93970 | <1% | 132 | $6K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 162 | $6K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 1,393 | $6K |
| 72100 | <1% | 330 | $6K | |
| 76830 | Ultrasound, transvaginal | <1% | 148 | $5K |
| 76770 | <1% | 186 | $5K | |
| 87040 | <1% | 549 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,030 | $5K |
| J1815 | Injection, insulin, per 5 units | <1% | 715 | $5K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 777 | $5K |
| 93017 | <1% | 220 | $5K | |
| 71271 | <1% | 57 | $5K | |
| 82803 | <1% | 271 | $4K | |
| 84703 | <1% | 675 | $4K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 494 | $4K |
| 85379 | <1% | 611 | $4K | |
| 94729 | <1% | 182 | $4K | |
| 81001 | <1% | 2,161 | $4K | |
| 94726 | <1% | 181 | $4K | |
| 93226 | <1% | 116 | $4K | |
| 96158 | <1% | 91 | $4K | |
| 64415 | <1% | 13 | $3K | |
| 82565 | <1% | 894 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,130 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 694 | $3K |
| 73560 | <1% | 323 | $3K | |
| J8501 | Aprepitant, oral, 5 mg | <1% | 392 | $3K |
| 82607 | <1% | 345 | $3K | |
| 73610 | <1% | 214 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,453 | $3K |
| 73030 | <1% | 258 | $3K | |
| 74178 | <1% | 14 | $3K | |
| 93975 | <1% | 26 | $3K | |
| 73630 | <1% | 347 | $3K | |
| 84439 | <1% | 421 | $3K | |
| 73502 | <1% | 204 | $3K | |
| 81025 | <1% | 1,088 | $2K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 170 | $2K |
| 82728 | <1% | 238 | $2K | |
| 86850 | <1% | 367 | $2K | |
| 96159 | <1% | 67 | $2K | |
| 74018 | <1% | 208 | $2K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 39 | $2K |
| 70486 | <1% | 40 | $2K | |
| 70491 | <1% | 28 | $2K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,132 | $2K |
| 84100 | <1% | 674 | $2K | |
| 85027 | <1% | 777 | $2K | |
| 94060 | <1% | 194 | $2K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 114 | $2K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 64 | $2K |
| 73130 | <1% | 217 | $2K | |
| 88342 | <1% | 78 | $2K | |
| 93225 | <1% | 116 | $2K | |
| 85652 | <1% | 758 | $2K | |
| 86140 | <1% | 705 | $1K | |
| 87186 | <1% | 311 | $1K | |
| 86618 | <1% | 96 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,402 | $1K |
| 83540 | <1% | 240 | $1K | |
| 86803 | <1% | 116 | $1K | |
| 87077 | <1% | 343 | $1K | |
| 82550 | <1% | 288 | $1K | |
| 82962 | <1% | 1,298 | $1K | |
| 84702 | <1% | 87 | $1K | |
| 84134 | <1% | 77 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,078 | $1K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 256 | $1K |
| 86901 | <1% | 368 | $1K | |
| 86900 | <1% | 369 | $1K | |
| 80051 | <1% | 243 | $1K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 197 | $989.76 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 54 | $948.42 |
| 81003 | <1% | 476 | $936.34 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 56 | $927.68 |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 15 | $905.39 |
| 72040 | <1% | 72 | $890.48 | |
| 82746 | <1% | 127 | $887.73 | |
| 97162 | <1% | 255 | $876.99 | |
| 84520 | <1% | 279 | $872.52 | |
| 87075 | <1% | 194 | $843.90 | |
| 83550 | <1% | 232 | $801.48 | |
| 87070 | <1% | 223 | $800.45 | |
| 73110 | <1% | 100 | $777.45 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 29 | $748.70 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,389 | $746.93 |
| 86038 | <1% | 56 | $707.68 | |
| 96156 | <1% | 13 | $700.65 | |
| 73700 | <1% | 12 | $694.40 | |
| 97166 | <1% | 154 | $656.81 | |
| 87081 | <1% | 173 | $598.17 | |
| 82947 | <1% | 263 | $588.49 | |
| 80047 | <1% | 76 | $560.86 | |
| 84145 | <1% | 61 | $537.56 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,584 | $518.74 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 13 | $502.92 |
| 82977 | <1% | 63 | $444.11 | |
| 76870 | <1% | 12 | $390.92 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,419 | $387.73 |
| 87205 | <1% | 161 | $378.73 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,410 | $378.64 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,101 | $329.06 |
| 87430 | <1% | 76 | $318.15 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,383 | $314.17 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 211 | $285.66 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 12 | $278.32 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 332 | $235.66 |
| 72110 | <1% | 12 | $226.93 | |
| 90715 | <1% | 17 | $216.22 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,010 | $215.67 |
| 73080 | <1% | 25 | $202.40 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,692 | $195.99 |
| 87147 | <1% | 13 | $158.40 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,043 | $158.23 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 101 | $158.11 |
| 76937 | <1% | 58 | $153.08 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 109 | $152.53 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,278 | $143.46 |
| 11102 | <1% | 15 | $142.57 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 341 | $142.01 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 43 | $131.41 |
| 87340 | <1% | 15 | $124.72 | |
| 82140 | <1% | 45 | $117.32 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,017 | $109.58 |
| 76942 | <1% | 157 | $95.04 | |
| 80329 | <1% | 12 | $92.73 | |
| 73562 | <1% | 13 | $90.75 | |
| 94761 | <1% | 236 | $79.70 | |
| 80305 | <1% | 18 | $79.02 | |
| G0008 | Administration of influenza virus vaccine | <1% | 12 | $77.00 |
| 87210 | <1% | 28 | $73.39 | |
| 84550 | <1% | 14 | $67.98 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 506 | $67.63 |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,031 | $64.20 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 355 | $63.93 |
| 87102 | <1% | 16 | $63.05 | |
| C9399 | Unclassified drugs or biologicals | <1% | 45 | $62.66 |
| 82043 | <1% | 13 | $61.60 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 293 | $50.69 |
| 82270 | <1% | 14 | $38.20 | |
| 96376 | <1% | 258 | $34.70 | |
| J2704 | Injection, propofol, 10 mg | <1% | 985 | $33.35 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 193 | $26.80 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,745 | $25.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,631 | $23.47 |
| 88304 | <1% | 135 | $22.95 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 512 | $19.35 |
| 97161 | <1% | 14 | $16.38 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 1,178 | $14.49 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 268 | $10.35 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 21 | $7.20 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 68 | $2.09 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 52 | $1.44 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | <1% | 15 | $0.05 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 28 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 72 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 120 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 100 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 197 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 154 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 1,336 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 44 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFRITZ, BRIAN (CFO)
| Provider | Location | Paid |
|---|---|---|
| UPMC Horizon | Greenville, PA | $8.63M |
| UPMC Jameson | New Castle, PA | $6.82M |
| UPMC Jameson | New Castle, PA | $3K |
| UPMC Horizon | Greenville, PA | $1K |
| UPMC ST. Margaret | Pittsburgh, PA | $948.62 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.